glp-1 news today 2025 obesity drug market GLP-1 Market Trends and Global Forecasts Report 2025: A $157.5 Bn Market by 2035 GLP-1 Drugs Market Size to

Retatrutide vs Semaglutide: Evidence-based comparison of the investigational triple GIP/GLP-1/glucagon agonist versus the FDA-approved GLP-1 agonist

Ozempic changed the conversation around weight loss in a way that almost nothing has in the past twenty years

Designed for Busy LifestylesWith just one glp-1 patch per day, you can integrate seamlessly into work, travel, or study

Results Twenty-eight RCTs were ultimately included for analysis, involving a total of 77,485 participants

manufactured in cGMP-certified facilities, third-party tested for purity, and non-GMO, gluten-free, with zero artificial additives or fillers

The real problem seems to be retention